Overview

CI-994 in Treating Patients With Advanced Myeloma

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CI-994 in treating patients who have advanced myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
National Cancer Institute (NCI)
Parke-Davis
Treatments:
Histone Deacetylase Inhibitors
Tacedinaline